The US approved the cheaper, generic version of a breakthrough HIV prevention drug
The U.S. Food and Drug Administration has approved the first generic version of Lenacapavir, a twice-yearly HIV prevention drug administered via injection, considered the closest thing the world has to a vaccine.
The approval paves the way for the breakthrough drug to reach millions of people who need it, particularly in the countries hit hardest by the AIDS epidemic.
According to the United Nations, the drug could be the key to ending the AIDS epidemic globally by 2030.
Why is this good news? Manufactured and available in the United States, Lenacapavir costs $28,000 a year, but the generic version will cost just $40 per person per year, and will be made available to 120 low- and middle-income countries through a global partnership.
Every fall, an entire island goes dark to save young seabirds. Since 2019, Corvo’s around 450 inhabitants switch off the lights for five nights to tackle the disastrous effects of artificial light on Cory’s shearwaters, a seabird endemic to the Atlantic Ocean.
LGBTQ+
Nicole Craine/The 19th
Trans and nonbinary candidates in six US states just made history
The world is getting more of its electricity from renewable sources
In order to swiftly and effectively fight the climate crisis, the world needs to switch from fossil fuels to low-carbon power: renewables like solar and wind, and nuclear power.
While nuclear is contributing increasingly less to the global mix, renewables are an entirely different story, and the rapid growth of solar and wind in particular has dramatically increased the amount of electricity coming from renewable sources.
In 2000, nuclear and renewables made up a similar share of global electricity — in the last 25 years, renewables have increased to 34% of the world’s electricity, up from around 18%.
*Some of these recommendations may include affiliate links, which means if you buy anything from this email, we may get something in return at no extra cost to you. (Thanks for your support!)
Get good news in your Google Search results in just two clicks!
Need help? Contact us for assistance. We’ve got your back.
You received this email because you signed up for the Goodnewsletter from Good Good Good — or because you followed a recommendation from another newsletter or ordered a Goodnewspaper.
To stop receiving The Goodnewsletter, unsubscribe. To opt in or out of other emails from Good Good Good, manage your email settings. To stop receiving all emails from Good Good Good — which may potentially include paid subscriber-exclusive content — you can opt out entirely.